ArticleThe journal of pathology. Clinical research2026
Validation of fibroblast activation protein and α-smooth muscle actin as prognostic biomarkers in prostate cancer through AI-assisted image analysis of dual-marker IHC.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prostate cancer (PCa) lacks reliable and accurate tissue-based biomarkers to support prognostic stratification and clinical treatment decisions. Current diagnostic assessment, including Gleason grading, has limitations such as interobserver variability and insufficient granularity for disease aggressiveness. Fibroblast activation protein (FAP) and α-smooth muscle actin (αSMA) have emerged as putative stromal biomarkers, but their prognostic value in localised PCa has not been validated at scale. In this study, we developed a novel artificial intelligence (AI)-augmented image analysis pipeline tailored for dual-marker immunohistochemistry of FAP and αSMA, enabling automated, tissue compartment-specific quantification of biomarker expression. This deep learning model was trained and validated using digitised high-resolution whole-slide images of tissue microarrays from three prostatectomy cohorts, comprising 4,097 cores from 835 patients with comprehensive clinical follow-up data. The AI pipeline demonstrated high accuracy in detecting epithelial, stromal, and immune compartments, as well as in quantifying FAP and αSMA signals. We validated stromal FAP as a robust prognostic marker consistently associated with adverse clinical outcomes, including earlier biochemical recurrence, metastasis, and cancer-specific death. Epithelial FAP and stromal αSMA showed additional prognostic associations in selected analyses, particularly in MRI-visible tumours. Our findings reinforce the biological and clinical relevance of stromal FAP in the prostate tumour microenvironment. By enabling standardised and scalable biomarker quantification, our newly developed AI-assisted workflow advances the clinical utility of FAP and αSMA and demonstrates the power of integrating digital pathology with biomarker quantification. This study represents a critical step toward implementing stromal biomarkers in routine PCa diagnostics and underscores the potential of AI-enhanced histopathology in advancing precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.